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Human genetics is revealing ever more variants that influence propensity to common diseases, but progress
in translating these discoveries into the biological mechanisms responsible for predisposition continues to
lag behind. A recent paper in Cell (Boj et al., 2012) using rodent models to examine how diabetes-associated
variants near TCF7L2 perturb metabolic regulation provides surprising results.Incomplete understanding of the physio-
logical mechanisms involved in the devel-
opment of type 2 diabetes (T2D) frustrates
efforts to develop more effective strate-
gies for prevention and treatment. Individ-
uals with T2D characteristically display
a constellation of metabolic abnormalities
contributing to disturbed glucose regula-
tion—including deficient secretion of
insulin from the pancreatic b cells and
reduced capacity of insulin to regulate
metabolic processes in target tissues
such as liver, fat, and muscle. However,
the relationship between these apparently
distinct derangements remains uncertain.
Human genetics can help to disentangle
such complex pathophysiological prob-
lems: for example, exploration, in nondia-
betic subjects, of the metabolic effects of
DNA variants shown to influence risk of
T2D can illuminate critical, early steps in
metabolic decompensation. For the 70
or so genetic regions now implicated in
T2D predisposition, such studies have
generally pointed toward the primacy of
defects in insulin secretion. Evidence for
a b cell mechanism has seemed particu-
larly compelling for the T2D association
signal which maps intronic to TCF7L2,
the gene encoding the transcription
factor TCF4. This signal has particular
salience, as the variants concerned have
a relatively large effect on T2D risk (a
30% increase per risk allele). However, a
recent paper examining the metabolic
effects of perturbing expression of the
murine homolog, Tcf7l2, suggests a more
complex picture (Boj et al., 2012).Boj and colleagues (Boj et al., 2012)
demonstrate that manipulation of islet
Tcf7L2 expression in adult mice (using
the rat insulin promoter to restrict induc-
ible knockdown of transcript expression
to the insulin-secreting pancreatic b cells)
has no demonstrable effects on glucose-
stimulated insulin secretion. Instead,
they report that, in both global knockout
mice and in liver-specific inducible
models, depletion of Tcf7L2 is asso-
ciated with hypoglycaemia and reduced
hepatic glucose production. Conversely,
overexpression of Tcf7l2 in liver leads to
enhanced hepatic glucose production
and to glucose intolerance. The authors
argue that TCF7L2-related disruption of
b cell function is probably the indirect
consequence of primary events in liver
and elsewhere (see Figure 1).
On the face of it, these findings
run counter to much of the existing
evidence, from both humans and rodents.
Physiological studies in nondiabetic
human subjects have consistently shown
that TCF7L2 T2D risk alleles confer
a metabolic picture dominated by
reduced insulin secretion (Lyssenko
et al., 2007). This is accompanied by
a blunted response to incretins such as
GLP-1, which have an important physio-
logical role in boosting insulin secretion
following meals. Diabetes-associated
variation at TCF7L2 has also been associ-
ated with altered pancreatic islet mor-
phology (Le Bacquer et al., 2012) and, in
human islet culture studies, with disrup-
tion of glucose-stimulated insulin secre-Cell Metabolism 17tion (Lyssenko et al., 2007; Rosengren
et al., 2012; Le Bacquer et al., 2012).
Molecular studies have revealed that the
specific base change most strongly impli-
cated in T2D risk in Europeans alters
chromatin accessibility at a site involved
in genomic regulation in islets, but not
other tissues (Gaulton et al., 2010). These
data indicate a clear relationship between
TCF7L2 variants implicated in T2D risk
and altered islet function. Furthermore,
they suggest that these effects are
islet autonomous, rather than driven by
changes in other tissues (see Figure 1).
The new data also appear at odds with
other rodent studies. RNAi-based knock-
down of Tcf7L2 in rodent islets and b cell
lines results in reduced insulin release,
possibly due to defective insulin granule
exocytosis (da Silva Xavier et al., 2009),
and pancreas-specific Tcf7l2 null mice
display islet phenotypes—reduced insulin
secretion, blunted incretin response,
impaired b cell expansion—redolent of
those seen in humans carrying TCF7L2
risk alleles (da Silva Xavier et al., 2012).
Unlike the inducible b cell-specific
knockout model studied by Boj and
colleagues (Boj et al., 2012), silencing of
Tcf7l2 expression in these pancreas-
specific null mice involves other islet
endocrine cells and pancreatic exocrine
tissue, and extends through embryonic
life as well as adulthood. Perhaps more
extensive disruption of pancreatic devel-
opment and/or loss of crosstalk between
these different cell types is required for
full expression of the islet phenotype., February 5, 2013 ª2013 Elsevier Inc. 157
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Figure 1. Alternative Models for Mechanisms Linking TCF7L2 to T2D Pathogenesis
(A) Islet-centric model: most of the evidence to date has indicated that the critical feature associated with
sequence or expression changes in and around TCF7L2 is one of pancreatic islet dysfunction, with other
changes likely secondary.
(B) Hepatocentric model: the recent paper by Boj and colleagues (Boj et al., 2012) suggests that the
major changes in metabolic regulation following disruption of TCF7L2 expression are hepatic rather
than pancreatic.
(C) Multicentric model: the overall pattern of findings is consistent with independent pancreatic and
hepatic contributions to T2D pathogenesis.
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PreviewsAlternatively, it may simply be that varia-
tion in phenotype reflects subtle differ-
ences in mouse strains or environment:
similar divergence of phenotypic expres-
sion has been observed in murine studies
of other T2D risk loci.
What other explanations are consistent
with this body of data? First, it is entirely
possible that perturbation of TCF7L2
expression influences homeostatic pro-
cesses in both pancreas and liver (see
Figure 1). While human physiological
studies have highlighted deficient insulin
secretion, a concomitant increase in
hepatic glucose output has been reported
(Lyssenko et al., 2007). If the T2D risk vari-
ants near TCF7L2 have independent158 Cell Metabolism 17, February 5, 2013 ª2effects involving multiple tissues, models
of tissue-specific perturbation, however
powerful in other settings, may fail to do
justice to the complex temporal and
spatial interplay that is central to mainte-
nance of glucose homeostasis.
Second, and as some of the studies
above demonstrate, there is remarkably
little consistency regarding the directional
relationship between TCF7L2 expression
and glucose intolerance. While some
rodent studies have demonstrated that
reduced Tcf7l2 expression results in dia-
betes (da Silva Xavier et al., 2009), others
have found the opposite (Savic et al.,
2011). In humans, limited islet expression
data suggest that individuals carrying T2D013 Elsevier Inc.risk alleles at TCF7L2, and those with T2D
itself, have increased TCF7L2 transcript
levels (Lyssenko et al., 2007). However,
in human islets, impaired glucose-stimu-
lated insulin secretion has been reported
following both TCF7L2 suppression (Shu
et al., 2008) and overexpression (Lys-
senko et al., 2007). These divergent
effects raise concerns about the biolog-
ical relevance of perturbing total tran-
script levels. T2D risk variants have been
proposed to influence TCF7L2 splicing
patterns, and it may be the ratio of func-
tionally distinct mRNA isoforms, rather
than the overall level of expression, which
defines their phenotypic consequences
(Hansson et al., 2010). More complex,
‘‘humanized’’ models will be required to
explore this.
Finally, it is worth emphasizing that we
have only circumstantial evidence that
these T2D risk variants mediate their
metabolic effects through TCF7L2.
Experimental manipulation of TCF7L2
will be of limited value if other regional
transcripts regulated by these variants
contribute themajor diabetogenic impact.
This is a question that may be settled
by resequencing studies: identification
of human subjects who carry alleles dis-
rupting the TCF7L2 coding sequence
(assuming these are compatible with life)
would enable direct exploration of the
phenotypic consequences of isolated
TCF7L2 dysfunction.
These intriguing findings provide a
timely reminder of the difficulties which
attend the generation of robust biological
inference from the (mostly noncoding,
mostly modest effect) risk variants that
have recently been implicated in common
disease. In the 7 years since the TCF7L2
signal was discovered, over 60 additional
loci have been shown to influence T2D
predisposition. However, for most, as
with TCF7L2, the processes that link this
variation to diabetes risk remain unclear.
Novel approaches that address the
evident complexity of these systems will
be key if the field is to make progress in
understanding and combating T2D and
other complex diseases.REFERENCES
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Cancer cells reprogram their metabolism to support a high proliferative rate. A new study shows that, upon
serine starvation, the tumor suppressor p53 activates p21 to shift metabolic flux from purine biosynthesis to
glutathione production, which enhances cellular proliferation and viability by combating ROS (Maddocks
et al., 2013).Cancer cells have designated hallmarks
differentiating them from nonneoplastic
cells: genomic instability, resistance to
cell death, uncontrolled proliferation,
and metabolic reprogramming, to
name a few (Hanahan and Weinberg,
2011). The latter has been gaining
increased attention. Cancer cells can
reprogram their metabolism by shifting
from oxidative phosphorylation to aerobic
glycolysis, which defines the Warburg
effect (Ward and Thompson, 2012).
Although aerobic glycolysis produces
far less ATP, an increase in macromole-
cule production along with an avoid-
ance of heightened ROS accumulation
from oxidative phosphorylation have
been postulated for this metabolic re-
programming (Vander Heiden et al.,
2009). Recent advances have shown
that several features of altered metabo-
lism can be dictated by specific onco-
genes or tumor suppressors (Ward
and Thompson, 2012). Classically known
for inhibiting malignant transformationby regulating DNA repair, cell-cycle
arrest, and apoptosis, the tumor
suppressor p53 also upregulates meta-
bolic targets to inhibit tumorigenesis (Li
et al., 2012). Further, recent evidence
suggests that p53 may also regulate
glycolysis and oxidative phosphorylation
in a cell- and context-specific manner
(Gottlieb and Vousden, 2010). In an
elegant study conducted by Karen Vous-
den’s group, Maddocks et al. demon-
strate that serine starvation activates
p53 to reprogram metabolism and
increase cancer cell survival (Maddocks
et al., 2013).
Reprogramming metabolic flux makes
cancer cells increasingly dependent on
specific metabolites; de novo serine
synthesis has been recently shown to be
crucial for cancer cell proliferation and
survival (Chaneton et al., 2012; Locasale
et al., 2011). Under serine starvation
conditions, Maddocks et al. initially ob-
served a decrease in cell proliferation
and survival that was more pronouncedin p53-deficient colon cancer cells com-
pared to isogenic p53 wild-type cells.
When these tumor cells were xenografted
in nude mice fed a diet lacking serine,
p53-deficient tumors exhibited a stronger
decrease in tumor volume than wild-
type tumors (Maddocks et al., 2013). It
has recently been shown that serine
deprivation forces cancer cells into a
‘‘fuel-efficient mode’’ where the glycolytic
intermediate 3-phosphoglycerate (3-PG)
shuttles into the Serine Synthesis Path-
way (SSP), while pyruvate enters the
TCA cycle, thereby increasing oxidative
phosphorylation and limiting the produc-
tion of lactate (Chaneton et al., 2012).
Maddocks et al. found that SSP enzymes
were similarly activated upon serine
starvation, independent of p53 status,
ruling out a defective SSP and subse-
quent improper de novo serine synthesis
as a potential candidate for the observed
proliferative failure in p53/ cells (Mad-
docks et al., 2013). Using oxygen
consumption as a read-out for oxidative, February 5, 2013 ª2013 Elsevier Inc. 159
